Jefferies resumed coverage on Ascendis Pharma
$ASND
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies resumed coverage of Ascendis Pharma with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $355.00 | Buy | Citigroup |
| 3/16/2026 | Buy | Jefferies | |
| 1/28/2026 | $342.00 | Overweight | Barclays |
| 11/18/2025 | $255.00 | Peer Perform | Wolfe Research |
| 10/17/2025 | $271.00 | Strong Buy | Raymond James |
| 7/3/2025 | $250.00 | Overweight | Morgan Stanley |
| 5/5/2025 | $250.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/16/2025 | $205.00 | Outperform | RBC Capital Mkts |
Citigroup initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $355.00
Jefferies resumed coverage of Ascendis Pharma with a rating of Buy
Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial demonstrated significantly greater annualized growth velocity (AGV) compared to placebo at Week 52, and sustained these growth improvements through up to two years of treatment. The safety profile for this subgroup through up to two years of treatment was similar to the overall population, with a low rate of injection site reactions (ISRs, all mild), no symptomatic hypotension, and no acceleration of
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce
SD - Ascendis Pharma A/S (0001612042) (Filer)
SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
4 - Ascendis Pharma A/S (0001612042) (Issuer)
TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to
TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Me
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growt
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)